We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals

145 hedge funds and large institutions have $1.53B invested in Lexicon Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 50 increasing their positions, 38 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

219% more call options, than puts

Call options by funds: $7.88M | Put options by funds: $2.47M

106.32% more ownership

Funds ownership: 0%106.32% (+106%)

35% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 20

32% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 38

2% more funds holding

Funds holding: 142145 (+3)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

23% less capital invested

Capital invested by funds: $2B → $1.53B (-$468M)

Holders
145
Holders Change
+3
Holders Change %
+2.11%
% of All Funds
3.63%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
27
Increased
50
Reduced
38
Closed
20
Calls
$7.88M
Puts
$2.47M
Net Calls
+$5.41M
Net Calls Change
-$8.08M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
26
Wellington Management Group
Massachusetts
$3.48M +$1.67K +104 +0%
Bank of America
27
Bank of America
North Carolina
$3.48M +$894K +55,704 +28%
Millennium Management
28
Millennium Management
New York
$3.14M -$3.74M -233,098 -51%
TCIM
29
TIAA CREF Investment Management
New York
$3.11M -$1.12M -69,950 -24%
CS
30
Candriam SCA
Luxembourg
$2.7M
AllianceBernstein
31
AllianceBernstein
Tennessee
$2.64M -$240K -14,970 -7%
Goldman Sachs
32
Goldman Sachs
New York
$2.35M +$747K +46,581 +38%
BIM
33
BlackRock Investment Management
Delaware
$2.15M -$642 -40 -0%
Citigroup
34
Citigroup
New York
$2.09M +$2M +124,391 +466%
GCP
35
GSA Capital Partners
United Kingdom
$2.01M +$880K +54,850 +61%
Morgan Stanley
36
Morgan Stanley
New York
$1.97M +$348K +21,709 +18%
BA
37
BlackRock Advisors
Delaware
$1.86M +$208K +12,972 +11%
California Public Employees Retirement System
38
California Public Employees Retirement System
California
$1.73M
First Trust Advisors
39
First Trust Advisors
Illinois
$1.67M -$70.2K -4,375 -3%
UBS Group
40
UBS Group
Switzerland
$1.66M +$1.36M +84,892 +244%
Bank of Montreal
41
Bank of Montreal
Ontario, Canada
$1.64M +$1.46M +91,217 +556%
Wells Fargo
42
Wells Fargo
California
$1.53M -$1.66M -103,473 -48%
TA
43
Teachers Advisors
New York
$1.48M +$439K +27,378 +34%
AQR Capital Management
44
AQR Capital Management
Connecticut
$1.31M -$307K -19,134 -17%
Russell Investments Group
45
Russell Investments Group
United Kingdom
$1.24M +$1.44M +89,797 New
D.E. Shaw & Co
46
D.E. Shaw & Co
New York
$1.22M -$9.29M -579,178 -87%
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$1.21M -$36.9K -2,300 -3%
AP
48
AHL Partners
United Kingdom
$1.18M +$712K +44,374 +108%
Swiss National Bank
49
Swiss National Bank
Switzerland
$1.11M
ProShare Advisors
50
ProShare Advisors
Maryland
$1.04M +$72.5K +4,517 +6%

LXRX Hedge Fund Activity: Q4 2016 in Review

145 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2016, worth a combined $1.53B — down 23% from $2B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new LXRX positions and 20 closed out — a net gain of 7 holders — while 50 added to existing stakes and 38 trimmed.

The largest buyer was Eagle Asset Management, adding an estimated $18.3M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $17.1M sold.

  • 145 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2016, up from 142 in Q3 2016.
  • Funds reported $1.53B of Lexicon Pharmaceuticals stock for Q4 2016, down 23% quarter-over-quarter.
  • 27 funds opened new Lexicon Pharmaceuticals positions in Q4 2016 and 20 closed out, a net change of +7 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q4 2016 was Eagle Asset Management, an estimated $18.3M added.
  • The largest Lexicon Pharmaceuticals seller in Q4 2016 was Arrowstreet Capital, an estimated $17.1M sold.

Based on aggregated 13F filings for Q4 2016.